医学
阿司匹林
危险系数
加药
心肌梗塞
随机对照试验
内科学
冲程(发动机)
临床试验
比例危险模型
置信区间
机械工程
工程类
作者
Catherine P. Benziger,Amanda Stebbins,Lisa Wruck,Mark B. Effron,Guillaume Marquis‐Gravel,Peter Farrehi,Saket Girotra,Kamal Gupta,Sunil Kripalani,Daniel Muñoz,Tamar S. Polonsky,Amber Sharlow,Jeff Whittle,Robert A. Harrington,Russell L. Rothman,Adrian F. Hernandez,W. Schuyler Jones
出处
期刊:JAMA Cardiology
[American Medical Association]
日期:2024-07-10
标识
DOI:10.1001/jamacardio.2024.1712
摘要
Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality in the US. Although aspirin is recommended for secondary prevention of ASCVD, there was no difference in safety and effectiveness of aspirin dosed daily at 81 mg or 325 mg in the ADAPTABLE (Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness) randomized clinical trial. However, it is unknown whether differences by sex exist in the safety and effectiveness of the different aspirin doses.
科研通智能强力驱动
Strongly Powered by AbleSci AI